Canal, Clinton E. Archives • Fragile X Research

Targeting Serotonin 1A Receptors in Fmr1 Knockout Mice

FRAXA Research Foundation 2022 Grants • Canal, Clinton E. • Current Research Grants • Mercer University • Saraf, Tanishka • Treatment Targets August 30, 2022January 26, 2023drug repurposing, hyperexcitability, NIH, seizure, serotonin

Dr. Canal has discovered a promising treatment approach for Fragile X syndrome: new compounds which specifically and potently boost serotonin in the brain. The target is the brain’s serotonin 1A receptor.

FRAXA Research Grants Drive Big Investments in Fragile X

Dave Bjork Bhattacharyya, Anita • Canal, Clinton E. • Kaczmarek, Leonard • Research Updates • Zhao, Xinyu March 28, 2018November 22, 2021Autifony Therapeutics, FRAXA-DVI, Fulcrum Therapeutics, seizure, serotonin, sound

Most people know that FRAXA supports academic research at many institutions such as Harvard University, University of Pennsylvania, Massachusetts Institute of Technology, and Yale University. However, FRAXA is also working with more than 30 pharmaceutical companies around the world. Mike spends a lot of his time advising and collaborating with industry partners.

Quantitative Assessment of the Serotonin System in a Mouse Model of Fragile X Syndrome

FRAXA Research Foundation 2017 Grants • 2018 Grants • 2019 Grants • Canal, Clinton E. • Completed Research Grants • Disease Mechanisms • Drug Repurposing • Mercer University September 27, 2017March 10, 2021autism, serotonin

FRAXA Research Foundation awarded a grant of $90,000 over two years to Clinton Canal, PhD. Dr. Canal, previously a research assistant professor at Northeastern University, has just launched his own lab at Mercer University in Atlanta, GA, to focus on Fragile X research.

Targeting Serotonin Receptors to Treat Behavioral and Psychological Symptoms

Theodore Coutilish Canal, Clinton E. • Disease Mechanisms • Drug Repurposing • Mercer University • Research Updates August 1, 2017June 15, 2018drug repurposing, serotonin

With a $90,000 grant from FRAXA Research Foundation awarded in 2017, Dr. Clinton Canal targets seratonin receptors. “There are 15 unique serotonin receptors (at least) and many of them impact the function of brain circuits that are impaired in neurodevelopmental and psychiatric disorders,” said Dr. Canal. “Results from this project could guide new drug discovery or drug repurposing for Fragile X.”